Persistence of seroconversion at 6 months following primary immunisation in patients with immune-mediated inflammatory diseases

Luuk Wieske, Eileen W. Stalman*, P. J.Koos Van Dam, Laura Y. Kummer, Maurice Steenhuis, Zoe L.E. Van Kempen, Joep Killestein, Adriaan G. Volkers, Sander W. Tas, Laura Boekel, Gertjan Wolbink, Anneke Van Der Kooi, Joost Raaphorst, Mark Löwenberg, Bart Takkenberg, Geert R.A.M. D'Haens, Phyllis I. Spuls, Marcel W. Bekkenk, Annelie H. Musters, Nicoline F. PostAngela L. Bosma, Marc L. Hilhorst, Yosta Vegting, Frederique J. Bemelman, Alexandre Voskuyl, Bo Broens, Agner Parra Sanchez, Cécile A.C.M. Van Els, Jelle De Wit, Abraham Rutgers, Karina De Leeuw, Barbara Horváth, Jan J.G.M. Verschuuren, Annabel M. Ruiter, Lotte Van Ouwerkerk, Diane Van Der Woude, Cornelia F. Allaart, Y. K.Onno Teng, Pieter Van Paassen, Matthias H. Busch, Papay B.P. Jallah, Esther Brusse, Pieter A. Van Doorn, Adája Elisabeth Baars, Dirkjan Hijnen, Corine R.G. Schreurs, W. Ludo Van Der Pol, H. Stephan Goedee, Sofie Keijzer, Jim Keijser, Olvi Cristianawati, Anja Ten Brinke, Niels J.M. Verstegen, Koos A.H. Zwinderman, S. Marieke Van Ham, Taco W. Kuijpers, Theo Rispens, Filip Eftimov

*Corresponding author for this work

Research output: Contribution to journalLetterAcademicpeer-review

Original languageEnglish
Pages (from-to)883-885
Number of pages3
JournalAnnals of the rheumatic diseases
Volume82
Issue number6
DOIs
Publication statusPublished - 1 Jun 2023

Keywords

  • Autoimmune Diseases
  • Covid-19
  • Tumor Necrosis Factor Inhibitors
  • Vaccination

Cite this